
Interim Report

Quarter 1, 2025





Essity Aktiebolag (publ)

Solid performance with higher sales and strong cash flow

Quarter 1, 2025

- Net sales increased 0.4% to SEK 34,976m (34,850)
- Organic sales growth amounted to 2.1%, of which volume accounted for 0.0% and price/mix 2.1%.
- EBITA increased 4% to SEK 4,718m (4,523)
- EBITA excl. IAC decreased 4% to SEK 4,706m (4,880). Excluding currency translation effects, EBITA excl. IAC decreased by 2%.
- EBITA margin excl. IAC decreased 0.5 percentage points to 13.5% (14.0)
- ROCE amounted to 16.7% (15.9) and ROCE excl. IAC to 16.7% (17.2)
- Profit for the period, total operations, amounted to SEK 3,083m (11,493)
- Earnings per share, continuing operations, increased to SEK 4.43 (3.51). Earnings per share, total operations, decreased to SEK 4.43 (16.21).
- After the end of the first quarter, it was announced that Essity's Board of Directors had resolved on a new share buyback program for SEK 3bn beginning on April 24, 2025.



2.1%

13.5%

Organic sales growth

EBITA margin excl. IAC

Financial overview, continuing operations

	2025:1	2024:1	%
Net sales, SEKm	34,976	34,850	0
Organic sales growth, %	2.1	-4.0	
EBITA, SEKm	4,718	4,523	4
EBITA margin, %	13.5	13.0	
EBITA excl. IAC, SEKm	4,706	4,880	-4
EBITA margin excl. IAC, %	13.5	14.0	
Profit for the period, SEKm	3,083	2,477	24
Earnings per share, SEK	4.43	3.51	26
Earnings per share*, SEK	4.65	4.33	7
ROCE, %	16.7	15.9	
ROCE excl. IAC, %	16.7	17.2	
Operating cash flow, SEKm	3,765	4,253	-11

^{*} Earnings per share excl. IAC and amortization of acquisition-related intangible assets

Financial overview, total operations

	2025:1	2024:1	%
Profit for the period, SEKm	3,083	11,493	-73
Earnings per share, SEK	4.43	16.21	-73
Net debt/EBITDA excl. IAC	1.02	1.34	

CEO's comments



Essity began the year with positive organic sales growth in all business areas, stable profitability and continued strong cash flow. In these turbulent times, Essity's strength becomes clear – with production close to our customers and consumers, we deliver leading hygiene and health solutions that are needed every day.

Higher sales and a strong product portfolio

All business areas reported positive organic sales growth for the first quarter of 2025 compared to the same period in 2024. Growth was primarily driven by higher prices. In Health & Medical and Consumer Goods, volumes were higher, while volumes were lower in Professional Hygiene, mainly due to lower demand in North America.

"We remain committed to our ambition to accelerate the company's profitable growth during the year."

During the quarter, we achieved product superiority of above 70%, meaning that customers and consumers rate Essity's products as the best in the market for more than 70% of the company's offerings. This is the highest percentage to date and the increase is the result of our latest product launches.

Stable profitability and strong cash flow

Earnings (EBITA excl. IAC) were slightly lower, mainly due to the higher cost of goods sold while higher sales prices increased earnings. EBITA margin excl. IAC was lower compared with the first quarter of 2024 but higher compared with the fourth quarter. Cash flow

continued to develop strongly, mainly due to the robust earnings, and the company's financial position is good.

New share buyback program

The share buyback program that began in June 2024 was completed during the quarter, resulting in approximately 10 million shares being repurchased for SEK 3bn. The Annual General Meeting in March 2025 resolved to cancel own shares, which also took place after the end of the first quarter. The aim is to continue buying back shares as a recurring part of Essity's capital allocation, and on April 23 the Board of Directors resolved on a new SEK 3bn program, beginning on April 24, 2025.

Limited impact from trade tariffs

Essity has sales in approximately 150 countries, but we expect that the changed trade tariffs will only have a limited impact on the company. Our production is close to our customers and consumers, with approximately 70 production facilities worldwide. For the parts of our operations that are nonetheless affected, we are reviewing our flows and actively striving to optimize our production and supply chain.

Looking ahead

We remain committed to our ambition to accelerate the company's profitable growth during the year. We will achieve this through value-creating innovation, strong brands, efficiency improvements and by continuing our successful sustainability work.

Magnus Groth

President and CEO

Group

Net sales

Net sales increased 0.4% in the first quarter of 2025 compared with the corresponding period a year ago and amounted to SEK 34,976m (34,850).

Organic sales growth increased by 2.1%. All business areas reported positive organic growth. Volumes were higher in Health & Medical and Consumer Goods. However, volumes were lower in Professional Hygiene, mainly due to lower demand in North America. Higher prices in all business areas had a positive impact on growth. The product mix was also favorable with increased sales of premium products in Professional Hygiene.

Growth was good in Europe, with positive growth in all business areas. Growth was also positive in Latin America, with high growth in Consumer Goods and Professional Hygiene. Growth was negative in North America.

Change in net sales

%	2025:1 vs 2024:1
Total	0.4
Volume	0.0
Price/Mix	2.1
Organic growth	2.1
Acquisitions	0.0
Divestments	0.0
Currency translation	-1.7

Operating profit

The gross margin increased 0.7 percentage points to 32.8% (32.1). The gross margin excl. IAC decreased 0.4 percentage points to 32.8% (33.2). The cost of goods sold increased, mainly due to higher raw material and distribution costs. Energy costs were slightly lower. Cost savings amounted to approximately SEK 82m. Earnings were positively impacted by higher sales prices and a positive mix.

EBITA increased 4% to SEK 4,718m (4,523) and EBITA excl. IAC decreased 4% to SEK 4,706m (4,880). Excluding currency translation effects, EBITA excl. IAC decreased by 2%. The EBITA margin excl. IAC declined to 13.5% (14.0). Sales, general and administration costs increased to 19.4% (19.2), of which marketing costs accounted for 5.2% (5.5).

IAC amounted to SEK 32m (-426) mainly attributable to restructuring.

Change in EBITA excl. IAC

	SEKm
EBITA excl. IAC 2024:1	4,880
Volume	39
Price/Mix	704
Cost of goods sold	-610
Sales & Admin	-166
Currency translation	-98
Other	-43
EBITA excl. IAC 2025:1	4,706


Net sales 2503 by business area



Net sales 2503 by region



Net sales





Financial items

Financial items decreased to SEK -373m (-607) mainly on account of lower average net debt.

Tax

The tax expense was SEK 1,025m (1,050), corresponding to a tax rate of 25.0% (29.8). The tax expense excl. IAC was SEK 1,016m (1,144), corresponding to a tax rate of 24.9% (28.9).

Profit for the period

Profit for the period, total operations, amounted to SEK 3,083m (11,493). Profit for the period, continuing operations, was SEK 3,083m (2,477).

Cash flow


Operating cash flow amounted to SEK 3,765m (4,253). Net cash flow for continuing operations was SEK 1,394m (21,081), and for total operations SEK 1,394m (20,614). During the quarter, Essity bought back 2,672,500 own Class B shares for a total amount of SEK 776m.

Operating cash flow statement

. •		
SEKm	2025:1	2024:1
Operating cash surplus	6,376	6,594
Change in inventories	-868	-557
Change in operating receivables	301	-306
Change in operating liabilities	-465	572
Investments in non-current assets, net	-1,133	-1,409
Restructuring costs, etc.	-280	-601
Investments in operating assets through leases	-166	-40
Operating cash flow	3,765	4,253
Financial items	-373	-607
Income taxes paid	-1,222	-1,013
Other	0	1
Cash flow from current operations	2,170	2,634
Acquisitions of Group companies and other operations	_	-17
Divestments of Group companies and other operations	_	23,908
Cash flow before transactions with shareholders	2,170	26,525
Dividend	_1)	-5,443
Dividend to non-controlling interests	_	-1
Repurchase of own shares	-776	_
Net cash flow, continuing operations	1,394	21,081
Net cash flow, discontinued operations	_	-467
Net cash flow, total operations	1,394	20,614

Dividend of SEK 5,711m resolved by the Annual General Meeting on March 27, 2025. Payment April 3, 2025.

Operating cash flow



Financial position

Net debt decreased by SEK 3,995m compared with December 31, 2024 and amounted to SEK 26,774m. The Group's interest-bearing gross debt amounted to SEK 36,407m (42,749) at the end of the quarter. The average maturity period was 3.9 (3.8) years.

Compared with December 31, 2024, working capital decreased to SEK 5,211m, mainly due to an approved but not paid dividend. Working capital amounted to 4% (7) of net sales.

Equity attributable to owners of the Parent company decreased SEK 9,021m compared with December 31, 2024. Profit for the period attributable to owners of the Parent company increased the equity of owners of the Parent company by SEK 3,069m. Net translation effects reduced equity by SEK 6,138m. The dividend of SEK 5,711m and the buyback of own shares of SEK 776m reduced equity attributable to owners of the Parent company. The Group's total equity decreased SEK 9,037m during the quarter.

Share buyback program

The SEK 3bn share buyback program, which began on June 17, 2024, was completed on March 13, 2025, when Essity had repurchased a total of 10,070,500 Class B own shares for SEK 3bn. As of March 31, 2025, Essity's holdings of own shares corresponded to 1.4% of the total number of shares outstanding. The Annual General Meeting on March 27, 2025 resolved to cancel own shares. After the end of the quarter, Essity therefore canceled 9,288,000 Class B own shares.


Net debt



Financial position

	2503	2403	2412
Working capital, SEKm	5,211	9,609	10,746
Capital employed, SEKm	106,478	116,439	119,510
Net debt, SEKm	26,774	34,263	30,769
Debt/equity ratio	0.34	0.42	0.35
Debt payment capacity, %	67	50	59
Net debt/EBITDA	1.04	1.46	1.19
Net debt/EBITDA excl. IAC	1.02	1.34	1.16

ROCE excl. IAC and ROE excl. IAC



Return

%	2025:1	2024:1
ROCE	16.7	15.9
ROCE excl. IAC	16.7	17.2
ROE	14.6	56.9
ROE excl. IAC	14.5	15.0

Change in net debt

SEKm	2503	2403	2412
Net debt at the beginning of the period	-30,769	-53,703	-53,703
Net cash flow	1,394	20,614	25,168
Remeasurements to equity	1,147	921	96
Investments in non-operating assets through leases	-319	-211	-581
Translation differences	1,773	-1,884	-1,749
Net debt at the end of the period	-26,774	-34,263	-30,769

Health & Medical

- Higher volumes and sales prices
- · Good growth in both Europe and North America
- · High growth in Medical Solutions

Net sales

Net sales increased organically by 1.7%. Volumes were higher and prices developed positively. The product mix was stable.

Growth was good in both Europe and North America.

In Incontinence Products Health Care, volumes were slightly higher while sales prices and the product mix were marginally negative.

Organic growth in Medical Solutions was mainly driven by higher volumes combined with increased sales prices. The product mix was stable. Growth was good in all three therapeutic areas (wound care, compression therapy and orthopedics).

EBITA excl. IAC

EBITA and the EBITA margin excl. IAC decreased. The cost of goods sold was higher, mainly driven by increased raw material costs. Higher volumes and sales prices had a positive impact on earnings, while investments in sales to drive growth increased costs. Currency translation effects had a negative impact on earnings of SEK 3m compared with the corresponding period a year ago.



During the quarter, an upgrade of TENA ProSkin all-in-one was launched within Incontinence Products Health Care. The product is uniquely designed to provide disabled persons increased comfort, dryness and leakage security. New ComfiStretch™ and DuoLock™ technologies provide a better fit and keep liquid away from the skin.

Change in net sales

%	2025:1 vs 2024:1
Total	1.4
Volume	1.3
Price/Mix	0.4
Organic growth	1.7
Acquisitions	0.0
Divestments	0.0
Currency translation	-0.3

Organic sales growth

	2025:1 vs	% of net	
<u></u> %	2024:1	sales	
Incontinence Products Health Care	-0.1	58	
Medical Solutions	4.2	42	


Financial overview

	2025:1	2024:1	%
Net sales, SEKm	6,936	6,842	1
Organic sales growth, %	1.7	2.6	
Gross profit margin excl. IAC, %	44.4	45.2	
EBITA excl. IAC, SEKm	1,231	1,290	-5
EBITA margin excl. IAC, %	17.7	18.9	
ROCE excl. IAC, %	14.7	15.4	
Operating cash flow, SEKm	1,232	1,330	-7


Net sales 2503 by region



Net sales



EBITA excl. IAC



Consumer Goods

- Higher volumes and sales prices
- High growth in Latin America
- Strong growth in Incontinence Products Retail and Feminine Care

Net sales

Net sales increased organically 2.9%, driven by higher volumes and sales prices.

Growth was good in Europe and high in Latin America.

Incontinence Products Retail and Feminine Care reported high organic growth, primarily driven by strong volume growth and also higher sales prices. In Baby Care, volumes were lower and the mix was negatively affected by an increased share of retailer brands. Growth in Consumer Tissue was mainly due to higher sales prices.

EBITA excl. IAC

EBITA and the EBITA margin excl. IAC declined, mainly due to the higher cost of goods sold. The cost increase was mainly attributable to higher raw material costs in Consumer Tissue. Higher volumes and sales prices, cost savings and lower energy costs contributed positively to earnings. Sales costs were slightly higher. Currency translation effects had a negative impact on earnings of SEK 106m compared with the corresponding period a year ago.



The TENA MEN Protective Boxer features a new design that provides a more comfortable and discreet fit. The product has built-in protection with SpeedDry Zone textile technology for fast absorption.

Change in net sales

	% 2025:1 vs 202	
	Total	-0.3
	Volume	1.2
_	Price/Mix	1.7
	Organic growth	2.9
	Acquisitions	0.0
	Divestments	0.0
	Currency translation	-3.2

Organic sales growth

%	2025:1 vs 2024:1	% of net sales
Incontinence Products Retail	6.9	15
Feminine Care	5.1	17
Baby Care	-6.5	8
Consumer Tissue	2.7	59


Financial overview

	2025:1	2024:1	%
Net sales, SEKm	19,285	19,338	0
Organic sales growth, %	2.9	-4.8	
Gross profit margin excl. IAC, %	29.5	30.4	
EBITA excl. IAC, SEKm	2,443	2,545	-4
EBITA margin excl. IAC, %	12.7	13.2	
ROCE excl. IAC, %	18.2	19.1	
Operating cash flow, SEKm	1,657	2,331	-29

Net sales 2503 by region



Net sales SEKm 30,000 25,000 20,000 15,000 10,000 5,000 0 2023:1 2023:2 2023:3 2023:4 2024:1 2024:2 2024:3 2024:4 2025:1 Net sales Organic sales growth %



Professional Hygiene

- Lower volumes
- · Strong growth in premium products
- Higher EBITA and margin, excl. IAC

Net sales

Net sales increased organically by 0.7%, primarily driven by higher sales prices. The product mix also remained favorable with an increased share of premium products. Volumes were lower, negatively affected by lower demand in North America.

Growth was good in Europe and high in Latin America.

EBITA excl. IAC

EBITA and the EBITA margin excl. IAC increased. Higher sales prices combined with the favorable mix trend and lower costs for energy had a positive impact on earnings. However, the total cost of goods sold was higher, mainly due to higher raw material costs. Lower volumes had a negative earnings effect. Sales costs were higher in order to drive growth. Currency translation effects had a positive impact on earnings of SEK 4m compared with the corresponding period a year ago.



Tork's strategic system comprising paper hand towels, soap and dispensers differentiates our offering from competitors. They are patented and offer substantial added value to our customers. They often reduce consumption, which is a benefit both from a cost and sustainability perspective.

Change in net sales

%	2025:1 vs 2024:1
Total	0.8
Volume	-3.6
Price/Mix	4.3
Organic growth	0.7
Acquisitions	0.0
Divestments	0.0
Currency translation	0.1


Financial overview

	2025:1	2024:1	%
Net sales, SEKm	8,757	8,686	1
Organic sales growth, %	0.7	-6.9	
Gross profit margin excl. IAC, %	31.0	29.9	
EBITA excl. IAC, SEKm	1,413	1,332	6
EBITA margin excl. IAC, %	16.1	15.3	
ROCE excl. IAC, %	22.0	21.4	
Operating cash flow, SEKm	1,054	780	35


Net sales 2503 by region



Net sales



EBITA excl. IAC



Other Group information

Sustainability

Sustainability is integrated into Essity's strategy and is a priority, with ambitious Group targets in several areas. The outcome for three of the targets is presented below. More information on these and other targets can be found in Essity's Annual Report.

Health and safety: 2025 target: -75 % vs 2019

Reduction in total recordable incident rate

2021	2022	2023	2024	Q1 2025
-45%	-39%	-58%	-66%	-58%

Total recordable incidents (TRI) include lost time accidents (LTA), restricted work cases (RWC) and medical treatment cases (MTC)

Science-based emissions targets: 2030 Target: -35 % vs 2016

Reduction in absolute greenhouse gas emissions, Scope 1 and 2

2021	2022	2023	2024	Q1 2025*
-16%	-17%	-27%	-27%	-27%

*Outcome for last 12 months

Sustainable innovations: Target: >50 % annually

Percentage leading to social and/or environmental improvements

2021	2022	2023	2024	Q1 2025
59%	68%	85%	87%	84%

Events during the quarter

President and CEO Magnus Groth will leave Essity during 2025

On January 22, 2025, Essity announced that Magnus Groth is to step down as CEO for Essity during 2025. Magnus Groth has a notice period of one year. He will continue as President and CEO of Essity until a successor is appointed.

Essity's 2025 Annual General Meeting

Essity's Annual General Meeting was held on March 27, 2025. The Meeting approved the Parent company income statement and balance sheet and the consolidated income statement and consolidated balance sheet for 2024. The meeting resolved on a dividend for the financial year 2024 of SEK 8.25 per share. Board members Maria Carell, Annemarie Gardshol, Magnus Groth, Jan Gurander, Torbjörn Lööf, Bert Nordberg, Barbara M. Thoralfsson and Karl Åberg were re-elected. Alexander Lacik and Katarina Martinson were elected as new directors. Ewa Biörling had declined re-election. Jan Gurander was elected as the Chairman of the Board. The meeting resolved to amend the articles of association, to reduce the share capital through cancellation of own shares and to increase the share capital through a bonus issue. The Annual General Meeting authorized the Board of Directors to decide on buyback of Essity Class B shares and to transfer shares bought back by the company. These authorizations are valid until the next Annual General Meeting.

Sustainability recognition

During the quarter, Essity received several awards for its sustainability activities. The company has been awarded a place on the Dow Jones Sustainability Index (DJSI), one of the world's most prestigious sustainability indices, and included on the global non-profit environmental organization CDP's "A List".

Events after the quarter

Essity decides on new share buyback program of SEK 3bn

On April 24, 2025, Essity announced that the company's Board of Directors has resolved to utilize the authorization granted by the Annual General Meeting on March 27, 2025, and initiate a new program to buy back Class B shares in Essity for SEK 3bn. The program begins on April 24, 2025 and extends until the 2026 Annual General Meeting at the latest. The share repurchase will be financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share buyback program will be managed by BofA Securities Europe SA, which will decide on the date for repurchasing independently from and outside of Essity's influence. Repurchasing will take place on Nasdag Stockholm in accordance with the stock exchange's issuer regulations and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission's Delegated Regulation 2016/1052 (Safe Harbour Regulation).

> Stockholm, April 24, 2025 Essity Aktiebolag (publ)

> > Magnus Groth
> > President and CEO

NB: This information is such information that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz. Public Relations Director. at 07:00 CET on April 24, 2025.

This report has not been reviewed by the company's auditors.

Financial statements

Condensed consolidated income statement

SEKm	2025:1	2024:1	%
Net sales	34,976	34,850	0
Cost of goods sold	-23,502	-23,283	
Items affecting comparability (IAC) - cost of goods sold	-10	-366	
Gross profit	11,464	11,201	2
Gross profit excl. IAC	11,474	11,567	-1
Sales, general and administration	-6,768	-6,689	
Items affecting comparability (IAC) - sales, general and administration	22	9	
Share of results of associates and joint ventures ¹⁾	_	2	
Operating profit before amortization of acquisition-related intangible assets (EBITA)	4,718	4,523	4
Operating profit before amortization of acquisition-related intangible assets (EBITA) excl. IAC	4,706	4,880	-4
Amortization of acquisition-related intangible assets	-256	-320	
Items affecting comparability (IAC) - acquisition-related intangible assets	20	-69	
Operating profit	4,482	4,134	8
Operating profit excl. IAC	4,450	4,560	-2
Share of results of associates and joint ventures ¹⁾	-1	_	
Financial items	-373	-607	
Profit before tax	4,108	3,527	16
Profit before tax excl. IAC	4,076	3,953	3
Income taxes	-1,025	-1,050	
Profit for the period, continuing operations	3,083	2,477	24
Profit for the period excl. IAC, continuing operations	3,060	2,809	9
Profit for the period, discontinued operations	_	9,016	NA
Profit for the period, total operations	3,083	11,493	-73
Items affecting comparability (IAC) before tax	32	-426	
Items affecting comparability (IAC) after tax	23	-332	
Tax on amortization of acquisition-related intangible assets	75	73	

¹⁾ Until 2024, the share of results of associates and joint ventures was recognized in operating profit. From 2025 onwards, these results will be recognized below operating profit.

SEKm	2025:1	2024:1
Earnings attributable to:		
Owners of the Parent company		
Profit for the period, continuing operations	3,069	2,463
Profit for the period, discontinued operations	-	8,920
Profit for the period, total operations	3,069	11,383
Non-controlling interests		
Profit for the period, continuing operations	14	14
Profit for the period, discontinued operations	_	96
Profit for the period, total operations	14	110
Earnings per share - owners of the Parent company		
Earnings per share before and after dilution effects, continuing operations, SEK	4.43	3.51
Earnings per share before and after dilution effects, discontinued operations, SEK	-	12.70
Earnings per share before and after dilution effects, total operations, SEK	4.43	16.21
Average numbers of shares before and after dilution effects, million	693.4	702.3

Essity Aktiebolag (publ)

Consolidated statement of comprehensive income

SEKm	2025:1	2024:1	%
Profit for the period, continuing operations	3,083	2,477	24
Profit for the period, discontinued operations	_	9,016	NA
Profit for the period, total operations	3,083	11,493	-73
Other comprehensive income for the period			
Items that will not be reclassified to the income statement			
Actuarial gains/losses on defined benefit pension plans	1,148	921	
Fair value through other comprehensive income	-1	1	
Income tax attributable to components in other comprehensive income	-284	-237	
Total, continuing operations	863	685	
Total operations	863	685	

SEKm	2025:1	2024:1
Items that have been or may be reclassified subsequently to the income statement		
Cash flow hedges:		
Result from remeasurement of derivatives recognized in equity	-160	-417
Transferred to profit or loss for the period	-16	592
Translation differences in foreign operations	-7,080	5,935
Gains/losses from hedges of net investments in foreign operations	942	-1,041
Income tax attributable to components in other comprehensive income	-175	165
Total, continuing operations	-6,489	5,234
Total, discontinued operations	_	-557
Total operations	-6,489	4,677
Other comprehensive income for the period, net of tax	-5,626	5,362
Of which, continuing operations	5,626	5,919
Of which, discontinued operations	_	-557
Total comprehensive income for the period	-2,543	16,855
Of which, continuing operations	-2,543	8,396
Of which, discontinued operations	_	8,459
Total comprehensive income attributable to:		
Owners of the Parent company	-2,527	16,330
Non-controlling interests	-16	525

Consolidated balance sheet

SEKm	Mar 31, 2025	Mar 31, 2024	Dec 31, 2024
ASSETS			
Non-current assets			
Goodwill	38,124	41,271	41,137
Intangible assets	19,343	21,968	20,734
Property, plant and equipment	45,097	47,328	48,304
Right-of-use assets	4,055	4,066	4,088
Investments in associates and joint ventures	330	309	351
Shares and participations	8	6	8
Surplus in funded pension plans	2,593	4,012	2,475
Non-current financial assets	221	123	128
Deferred tax assets	2,203	2,561	2,326
Other non-current assets	728	778	824
Total non-current assets	112,702	122,422	120,375
Current assets			
Inventories	18,493	19,031	18,914
Trade receivables	22,278	23,686	23,538
Current tax assets	1,446	1,294	1,673
Other current receivables	3,586	3,267	4,480
Current financial assets	2,893	5,003	5,342
Non-current assets held for sale	76	_	-
Cash and cash equivalents	9,767	11,373	10,962
Total current assets	58,539	63,654	64,909
Total assets	171,241	186,076	185,284

SEKm	Mar 31, 2025	Mar 31, 2024	Dec 31, 2024
EQUITY AND LIABILITIES			
Equity			
Owners of the Parent company			
Share capital	2,350	2,350	2,350
Reserves	6,768	13,685	13,224
Retained earnings including profit/loss for the period	70,175	65,682	72,740
Equity attributable to owner of the Parent company	79,293	81,717	88,314
Non-controlling interests	411	459	427
Total equity	79,704	82,176	88,741
Non-current liabilities			
Non-current financial liabilities	38,161	40,332	40,674
Provisions for pensions	1,571	2,537	2,578
Deferred tax liabilities	6,699	7,108	6,978
Other non-current provisions	400	433	507
Other non-current liabilities	516	1,051	516
Total non-current liabilities	47,347	51,461	51,253
Current liabilities			
Current financial liabilities	2,516	11,905	6,424
Trade payables	15,675	16,171	17,098
Current tax liabilities	1,364	2,475	1,442
Current provisions	1,211	1,453	1,377
Other current liabilities	23,424*	20,435	18,949
Total current liabilities	44,190	52,439	45,290
Total equity and liabilities	171,241	186,076	185,284

^{*)} Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025 as decided at the Annual General Meeting on March 27, 2025.

Consolidated statement of change in equity

SEKm	Mar 31, 2025	Mar 31, 2024	Dec 31, 2024
Equity attributable to owners of the Parent company			
Value, beginning of the period	88,314	70,846	70,846
Total comprehensive income for the period	-2,527	16,330	24,719
Dividend	-5,711*	-5,443	-5,443
Repurchase of own shares	-776	_	-2,224
Acquisition of non-controlling interests	-	_	-8
Transferred to cost of hedged investments	5	5	31
Revaluation effect upon acquisition of non-controlling interests	-12	-21	393
Value, end of period	79,293	81,717	88,314
Non-controlling interests			
Value, beginning of period	427	8,559	8,559
Total comprehensive income for the period	-16	525	558
Dividend	_	-1	-23
Divestment of non-controlling interests	_	-8,624	-8,624
Acquisition of non-controlling interests	_	_	-43
Value, end of period	411	459	427
Total equity, value end of period	79,704	82,176	88,741

^{*)} Dividend of SEK 5,711m resolved by the Annual General Meeting on March 27, 2025. Payment on April 3, 2025.

Total

Consolidated cash flow statement

SEKm	2503	2403
Operating activities		
Operating profit	4,482	4,134
Adjustments for non-cash items ¹⁾	1,875	2,154
Operating profit excluding non-cash items	6,357	6,288
Interest paid	-1,011	-951
Interest received	117	113
Other financial items	-32	181
Capitalized expenditures to fulfill contracts with customers	-118	-105
Change in liabilities relating to restructuring programs, etc.	-143	-189
Paid tax	-1,222	-1,013
Cash flow from operating activities before changes in working capital	3,948	4,324
Cash flow from changes in working capital		
Change in inventories	-868	-557
Change in operating receivables	301	-306
Change in operating liabilities	-465	572
Cash flow from operating activities, continuing operations	2,916	4,033
Cash flow from operating activities, discontinued operations	-	-368
Cash flow from operating activities, total operations	2,916	3,665
Investing activities		
Acquisitions of Group companies and other operations	_	-17
Divestments of Group companies and other operations	-	17,980
Investments in intangible assets and property, plant and equipment	-1,144	-1,399
Paid interest capitalized in intangible assets and property, plant and equipment	-6	-11
Sale of property, plant and equipment	17	1
Purchase and sale of financial assets with short maturities	2,863	-452
Cash flow from investing activities, continuing operations	1,730	16,102
Cash flow from investing activities, discontinued operations	_	-87
Cash flow from investing activities, total operations	1,730	16,015

SEKm	2503	2403
Financing activities		
Proceeds from borrowings ²⁾	42	34
Repayment of borrowings ²⁾	-4,227	-6,950
Payment of lease liabilities ²⁾	-289	-263
Change in borrowings with short maturities, etc. ²⁾	-413	-2,814
Dividend	_3)	-5,443
Dividend to non-controlling interests	_	-1
Repurchase of own shares	-776	
Cash flow from financing activities, continuing operations	-5,663	-15,437
Cash flow from financing activities, discontinued operations	-	-12
Cash flow from financing activities, total operations	-5,663	-15,449
Cash flow for the period, continuing operations	-1,017	4,698
Cash flow for the period, discontinued operations	-	-467
Cash flow for the period, total operations	-1,017	4,231
Cash and cash equivalents at the beginning of the period	10,962	6,927
Translation differences in cash and cash equivalents	-178	215
Cash and cash equivalents at the end of the period, total operations	9,767	11,373
1) Adjustments for non-cash items		
Adjustificities for from custificities		
SEKm	2503	2403
Depreciation/amortization and impairment of non-current assets	1,747	2,079
Depreciation of capitalized selling expenses	120	115
Gain/loss on sale of assets	-	8
Non-cash items relating to restructuring programs	2	61
Other	6	-109

²⁾ From the second quarter of 2024, changes in borrowings with short maturities, etc. are presented separately in the cash flow statement. From the fourth quarter of 2024, payments of lease liabilities are presented separately in the cash flow statement. The comparative figures have been restated.

1,875

2,154

³⁾ Dividend of SEK 5,711m resolved by the Annual General Meeting on March 27, 2025. Payment on April 3, 2025.

15

Consolidated cash flow statement, cont.

SEKm	2503	2403
Reconciliation with consolidated operating cash flow statement		
Cash flow for the period, continuing operations	-1,017	4,698
Proceeds from borrowings ¹⁾	-42	-34
Repayment of borrowings ¹⁾	4,227	6,950
Payment of lease liabilities ¹⁾	289	263
Change in borrowings with short maturities, etc. ¹⁾	413	2,814
Purchase and sale of financial assets with short maturities	-2,863	452
Net debt in acquired and divested operations	_	5,928
Investments in operating assets through leases	-166	-40
Accrued interest, etc.	553	50
Net cash flow according to consolidated operating cash flow statement	1,394	21,081

¹⁾ From the second quarter of 2024, changes in borrowings with short maturities, etc. are presented separately in the cash flow statement. From the fourth quarter of 2024, payments of lease liabilities are presented separately in the cash flow statement. The comparative figures have been restated.

Condensed financial statements, Parent company

Condensed Parent company income statement

SEKm	2503	2403
Administrative expenses	-199	-426
Other operating income	-7	12
Operating loss	-206	-414
Financial items	-672	11,278
Profit/loss before tax	-878	10,864
Income taxes	16	91
Profit/loss for the period	-862	10,955

Parent company statement of comprehensive income

SEKm	2503	2403
Profit/loss for the period	-862	10,955
Other comprehensive income for the period	_	_
Total comprehensive income for the period	-862	10,955

Condensed Parent company balance sheet

SEKm	Mar 31, 2025	Dec 31, 2024
Assets		
Intangible assets	0	0
Property, plant and equipment	11	12
Financial non-current assets	177,095	177,152
Total non-current assets	177,106	177,164
Total current assets	579	770
Total assets	177,685	177,934
Equity, provisions and liabilities		
Equity Restricted equity	2,350	2,350
Non-restricted equity	74,664*	82,013
Total equity	77,014	84,363
Untaxed reserves	827	827
Provisions	779	818
Non-current liabilities	35,824	37,877
Current liabilities	63,241*	54,049
Total equity, provisions and liabilities	177,685	177,934

^{*)} The Annual General Meeting on March 27, 2025 resolved to distribute SEK 5,711m to Essity's shareholders, which is recognized as a current liability at March 31, 2025.

Notes

Note 1 Accounting principles

This interim report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Corporate Reporting Board and RFR 2 for the Parent company. On January 1, 2025, the International Accounting Standards Board (IASB®) published amendments to IAS 21, The Effects of Changes in Foreign Exchange Rates: non-exchangeability, that entered into force following approval by the EU. Essity Aktiebolag (publ) applies this amendment, which has not had any material impact on the Group's or the Parent company's financial statements.

In other respects, the accounting principles and calculation methods applied correspond to those described in Essity's 2024 Annual Report.

Note 2 Risks and uncertainties

Processes for risk management

Essity's Board determines the Group's strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company's delegation structure, from the Board of Directors to the CEO and from the CEO to the Business Unit Presidents. This means that most operational risks are managed by Essity's business units at the local level, but they are centrally coordinated when considered necessary. The tools used for coordination consist primarily of the business units' regular reporting and the annual strategy process, which includes risks and risk management.

Essity's financial risk management is centralized, as is its internal bank for financial transactions conducted by Group companies and the management of the Group's energy risks. Financial risks are managed in accordance with the Group's Finance Policy, which is adopted by Essity's Board and, together with Essity's Energy Risk Policy, provides a management framework. Risks are continuously compiled and monitored to ensure compliance with these guidelines. Essity has also centralized other risk management.

Essity has a staff function for internal audit, which monitors compliance with the Group's policies.

Essity's risk exposure and risk management are described on pages 41–46 in the 2024 Annual Report and in the sections under environmental information and social information on pages 59–61. No significant changes have taken place that have affected the reported risks.

Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity's risk exposure, these are described under the heading "Events during the quarter" in the interim or year-end reports.

The introduction or escalation of trade disputes, such as the imposition of significantly higher tariffs by the US administration on imports from certain trading partners, and any subsequent retaliation by such trading partners, may have an impact on tariffs or other barriers imposed on importers of goods between territories. This could directly or indirectly affect the Group's financial position and operating results, by increasing the prices of its products, weakening consumer purchasing power or otherwise causing economic instability in the affected countries.

Note 3 Financial assets and liabilities

Measurement principles and classifications of financial instruments, as described in Essity's 2024 Annual Report, Note E1, were applied consistently throughout the reporting period. Financial liabilities are measured at amortized cost provided they are not part of a fair value hedge when they are recognized at fair value through profit or loss. The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and non-current liabilities is estimated to be equal to their carrying amount.

SEKm	Carrying amount in the balance sheet	Fair value	Carrying amount in the balance sheet	Fair value	Measurement level ¹⁾
	Mar 31, 2025	Mar 31, 2025	Dec 31, 2024	Dec 31, 2024	
Assets					
Derivatives	1,523	1,523	1,102	1,102	2
Non-current financial assets	102	102	109	109	1
Total assets	4.00=	4.005	1 011	4.044	
i otai assets	1,625	1,625	1,211	1,211	
Liabilities	1,625	1,625	1,211	1,211	
	1,625 3,324	3,324	3,304	1,211 3,304	2
Liabilities		·	·	·	2 2
Liabilities Derivatives	3,324	3,324	3,304	3,304	

¹⁾ No financial instruments have been classified to level 3.

Note 4 The share Number of shares

	2025:1	2024:1
Number of shares, end of period	702,342,489	702,342,489
Of which class A-shares	58,973,654	60,970,043
Of which class B-shares	643,368,835	641,372,446
Number of Class B shares held by Essity, end of period	10,070,500	0
Number of outstanding shares before and after dilution, end of period	692,271,989	702,342,489
Average number of Class B shares held by Essity, end of period	8,981,594	0
Average number of shares before and after dilution	693,360,895	702,342,489

At the Annual General Meeting on March 27, 2025, a resolution was passed to cancel the company's own shares, which was carried out after the end of the quarter. Following the cancellation of 9,288,000 Class B shares, Essity now has a total of 693,054,489 outstanding shares.

Note 5 Acquisitions and divestments

On March 21, 2024, Essity completed the divestment of its holding of 51.59% of shares in the Asian hygiene company Vinda International Holdings Limited (Vinda). The sales proceeds amounted to approximately HKD 14.6bn (SEK 19,360m).

Statement of profit for the period, discontinued operations

SEKm	2503	2403
Profit for the period, Vinda	_	217
Other profit for the period, Vinda	_	8,799 ¹⁾
Profit for the period, discontinued operations	-	9,016
¹⁾ Of which:		
Profit from divestment	_	8,366
Reclassification of realized translation differences after tax	-	748
Transaction cost	_	-226
Impairment of Essity owned intangible asset related to Vinda after tax	_	-89

Income statement, discontinued operations

SEKm	2503	2403
Net sales	_	4,533
Operating expenses	_	-4,261
Operating profit	-	272
Financial items	_	-27
Profit before tax	-	245
Income taxes	_	-28
Profit for the period, discontinued operations	_	217

²⁾ The measurement level refers to liabilities measured at fair value in a hedging relationship.

Note 5 cont.

Income statement, discontinued operations, cont.

SEKm	2503	2403
Profit for the period, discontinued operations attributable to:		
Owners of the Parent company	-	8,920
Non-controlling interests	-	96
Earnings per share, discontinued operations - Owners of the parent company		
Earnings per share, discontinued operations before and after dilution effects, SEK	-	12.70
Average numbers of shares before and after dilution, million	_	702.3

Note 6 Use of non-International Financial Reporting Standards (IFRS®) performance measures

Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by ESMA (European Securities and Markets Authority). These guidelines are to be applied for APMs not supported under IFRS.

This interim report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders to analyze the company's operations. These non-IFRS performance measures may differ from similarly titled measures among other companies. Essity's Annual Report 2024, pages 124–128, describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. Abbreviations are used in the report for the performance and return measures below.

Abbreviation	Complete expression
EBITA	Operating profit before amortization of acquisition-related intangible assets
EBITDA	Operating profit before depreciation and amortization of property, plant and equipment and intangible assets
IAC	Items affecting comparability
ROCE	Return on capital employed
ROE	Return on equity

Capital employed

SEKm	2503	2403	2412
Total assets	171,241	186,076	185,284
-Financial assets	-15,474	-20,511	-18,907
-Non-current non-interest bearing liabilities	-7,615	-8,592	-8,001
-Current non-interest bearing liabilities	-41,674*	-40,534	-38,866
Capital employed	106,478	116,439	119,510

⁾ Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025 as decided at the Annual General Meeting on March 27, 2025.

Working capital

SEKm	2503	2403	2412
Inventories	18,493	19,031	18,914
Trade receivables	22,278	23,686	23,538
Other current receivables	3,586	3,267	4,480
Trade payables	-15,675	-16,171	-17,098
Other current liabilities	-23,424*	-20,435	-18,949
Other	-47	231	-139
Working capital	5,211	9,609	10,746

¹⁾ Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025 as decided at the Annual General Meeting on March 27, 2025.

Note 6 cont.

Net debt

SEKm	2503	2403	2412
Surplus in funded pension plans	2,593	4,012	2,475
Non-current financial assets	221	123	128
Current financial assets	2,893	5,003	5,342
Cash and cash equivalents	9,767	11,373	10,962
Financial assets	15,474	20,511	18,907
Non-current financial liabilities	38,161	40,332	40,674
Provisions for pensions	1,571	2,537	2,578
Current financial liabilities	2,516	11,905	6,424
Financial liabilities	42,248	54,774	49,676
Net debt, total operations	26,774	34,263	30,769

EBITA

SEKm	2025:1	2024:1
Operating profit	4,482	4,134
-Amortization of acquisition-related intangible assets	256	320
-Items affecting comparability (IAC) - impairment of acquisition related intangible assets	-20	69
Operating profit before amortization and impairment of acquisition-related intangible assets (EBITA)	4,718	4,523
EBITA margin (%)	13.5	13.0
-Items affecting comparability (IAC) - cost of goods sold	10	366
-Items affecting comparability (IAC) - sales, general and administration	-22	-9
EBITA excl. IAC	4,706	4,880
EBITA margin excl. IAC (%)	13.5	14.0

EBITDA

SEKm	2025:1	2024:1
Operating profit	4,482	4,134
-Amortization of acquisition-related intangible assets	256	320
-Depreciation/amortization	1,227	1,219
-Depreciation right-of-use asset	282	267
-Impairment	3	_
-Items affecting comparability (IAC) - impairment net	-1	204
-Items affecting comparability (IAC) - impairment of acquisition-related intangible assets	-20	69
EBITDA	6,229	6,213
-Items affecting comparability (IAC) excluding depreciation/amortization and impairment	-11	153
EBITDA excl. IAC	6,218	6,366

Organic growth

SEKm	2025:1	2024:1
Organic sales growth	743	-1,461
Acquisitions	_	_
Divestments	-10	-693
Exchange rate effect ¹⁾	-607	651
Recognized change	126	-1,503

¹⁾ Consists solely of currency translation effects

Note 7 Segment reporting

The tables below show parts of the income statement broken down by operating segment: Health & Medical, Consumer Goods and Professional Hygiene.

SEKm					2025:1
	Health &	Consumer	Professional	Other	Total
	Medical	Goods	Hygiene	operations	Group
Net sales	6,936	19,285	8,757	-2	34,976
Cost of goods sold	-3,856	-13,589	-6,039	-18	-23,502
Sales, general and administration	-1,849	-3,253	-1,305	-361	-6,768
Share of results of associates and joint ventures	_	-	-	_	-
Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC	1,231	2,443	1,413	-381	4,706
Amortization of acquisition-related intangible assets	-193	-58	-5	0	-256
Operating profit/loss excl. IAC	1,038	2,385	1,408	-381	4,450
Items affecting comparability (IAC)	30	12	-10	0	32
Operating profit/loss	1,068	2,397	1,398	-381	4,482
Share of results of associates and joint ventures					-1
Financial items					-373
Tax expense for the period					-1,025
Profit for the period, continuing operations					3,083

SEKm					2024:1
	Health &	Consumer	Professional	Other	Total
	Medical	Goods	Hygiene	operations	Group
Net sales	6,842	19,338	8,686	-16	34,850
Cost of goods sold	-3,746	-13,465	-6,090	18	-23,283
Sales, general and administration	-1,806	-3,329	-1,265	-289	-6,689
Share of results of associates and joint ventures	_	1	1	_	2
Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC	1,290	2,545	1,332	-287	4,880
Amortization of acquisition-related intangible assets	-255	-60	-5	_	-320
Operating profit/loss excl. IAC	1,035	2,485	1,327	-287	4,560
Items affecting comparability (IAC)	-46	-265	-116	1	-426
Operating profit/loss	989	2,220	1,211	-286	4,134
Share of results of associates and joint ventures					_
Financial items					-607
Tax expense for the period					-1,050
Profit for the period, continuing operations					2,477

Other financial information

Group information by quarter

	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Net sales, SEKm	34,976	37,805	36,274	36,617	34,850	36,625	37,092	37,078	36,352
Organic sales growth, %	2.1	3.9	1.9	-0.9	-4.0	-0.7	2.4	7.7	15.9
Gross profit, SEKm	11,464	11,968	11,962	12,003	11,201	11,675	10,683	10,454	10,359
Gross profit excl. IAC, SEKm	11,474	12,074	11,826	12,150	11,567	11,720	11,670	10,809	10,321
EBITA, SEKm	4,718	4,585	5,130	5,237	4,523	4,611	3,497	4,131	4,368
EBITA excl. IAC, SEKm	4,706	4,969	5,097	5,398	4,880	4,853	5,147	4,617	4,281
Operating profit, SEKm	4,482	4,315	4,868	4,978	4,134	4,341	2,903	3,819	4,085
Profit for the period, SEKm	3,083	2,893	3,329	3,334	2,477	2,858	1,563	2,445	2,651
Operating cash flow, SEKm	3,765	3,297	6,453	3,239	4,253	5,914	6,054	2,847	2,870
ROCE, %	16.7	15.8	17.8	17.9	15.9	16.2	11.7	14.2	15.5
ROCE excl. IAC, %	16.7	17.1	17.7	18.5	17.2	17.1	17.2	15.8	15.2
Capital employed, SEKm	106,478	119,510	112,957	117,076	116,439	110,750	116,928	122,817	110,265
ROE, %	14.6	13.4	15.9	16.1	56.9	14.4	8.2	13.3	14.4
ROE excl. IAC, %	14.5	14.9	15.8	16.6	15.0	15.5	16.5	15.2	14.0
Debt/equity ratio, %	0.34	0.35	0.35	0.40	0.42	0.68	0.75	0.86	0.84
Equity/assets ratio, %	46	48	46	46	44	35	34	32	30
Net debt, SEKm	26,774	30,769	29,122	33,214	34,263	53,703	60,633	69,124	62,114
Earnings per share, SEK	4.43	4.13	4.73	4.72	3.51	4.04	2.20	3.46	3.75
Earnings per share excl. IAC, SEK	4.65	4.85	4.97	5.13	4.33	4.54	4.83	4.26	3.93
Equity per share, SEK	115	127	119	119	117	113	115	114	105

Margins (%)	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Gross margin	32.8	31.7	33.0	32.8	32.1	31.9	28.8	28.2	28.5
Gross margin excl. IAC	32.8	31.9	32.6	33.2	33.2	32.0	31.5	29.2	28.4
EBITA margin	13.5	12.1	14.1	14.3	13.0	12.6	9.4	11.1	12.0
EBITA margin excl. IAC	13.5	13.1	14.1	14.7	14.0	13.3	13.9	12.5	11.8
Operating margin	12.8	11.4	13.4	13.6	11.9	11.9	7.8	10.3	11.2
Operating margin excl. IAC	12.7	12.4	13.3	14.0	13.1	12.5	13.1	11.7	11.0
Financial net margin	-1.1	-1.1	-1.2	-1.3	-1.7	-1.4	-1.7	-1.6	-1.7
Profit margin	11.7	10.3	12.2	12.3	10.2	10.5	6.1	8.7	9.5
Profit margin excl. IAC	11.6	11.3	12.1	12.7	11.4	11.1	11.4	10.1	9.3
Income taxes	-2.9	-2.7	-3.1	-3.2	-3.0	-2.7	-1.9	-2.1	-2.2
Income taxes excl. IAC	-2.9	-2.8	-3.0	-3.3	-3.3	-2.9	-2.7	-2.5	-2.2
Net margin	8.8	7.6	9.1	9.1	7.2	7.8	4.2	6.6	7.3
Net margin excl. IAC	8.7	8.5	9.1	9.4	8.1	8.2	8.7	7.6	7.1

Information by business area

N	et	sa	les

SEKm	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Health & Medical	6,936	7,417	7,127	7,213	6,842	7,001	7,158	6,905	6,665
Consumer Goods	19,285	20,472	19,410	19,672	19,338	19,870	19,729	20,056	20,257
Professional Hygiene	8,757	9,923	9,729	9,729	8,686	9,752	10,184	10,123	9,422
Other	-2	-7	8	3	-16	2	21	-6	8
Total	34,976	37,805	36,274	36,617	34,850	36,625	37,092	37,078	36,352

Organic sales growth

%	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Health & Medical	1.7	5.6	2.8	4.5	2.6	4.3	5.8	8.0	10.6
Consumer Goods	2.9	4.5	3.0	-1.3	-4.8	-2.8	-0.4	5.7	14.8
Professional Hygiene	0.7	1.4	-0.8	-3.9	-6.9	0.1	5.7	11.7	22.6
Total	2.1	3.9	1.9	-0.9	-4.0	-0.7	2.4	7.7	15.9

EBITA excl. IAC

SEKm	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Health & Medical	1,231	1,361	1,386	1,472	1,290	1,125	1,188	947	777
Consumer Goods	2,443	2,245	2,285	2,434	2,545	2,585	2,395	2,417	2,400
Professional Hygiene	1,413	1,817	1,812	1,868	1,332	1,531	1,887	1,582	1,288
Other	-381	-454	-386	-376	-287	-388	-323	-329	-184
Total	4,706	4,969	5,097	5,398	4,880	4,853	5,147	4,617	4,281

EBITA margin excl. IAC

%	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Health & Medical	17.7	18.3	19.4	20.4	18.9	16.1	16.6	13.7	11.7
Consumer Goods	12.7	11.0	11.8	12.4	13.2	13.0	12.1	12.1	11.8
Professional Hygiene	16.1	18.3	18.6	19.2	15.3	15.7	18.5	15.6	13.7
Total	13.5	13.1	14.1	14.7	14.0	13.3	13.9	12.5	11.8

Capital employed

SEKm	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Health & Medical	32,366	34,566	33,112	34,245	34,153	32,762	34,956	36,532	34,472
Consumer Goods	52,093	55,293	52,560	54,342	54,612	52,009	54,676	56,725	52,926
Professional Hygiene	25,494	25,998	24,501	25,976	25,663	24,021	25,765	28,225	27,500
Other	-3,475*	3,653	2,784	2,513	2,011	1,958	1,531	1,335	-4,633**
Total	106,478	119,510	112,957	117,076	116,439	110,750	116,928	122,817	110,265

⁹ Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025 as decided at the Annual General Meeting on March 27, 2025.

ROCE excl. IAC

%	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Health & Medical	14.7	16.1	16.5	17.2	15.4	13.3	13.3	10.7	9.1
Consumer Goods	18.2	16.7	17.1	17.9	19.1	19.4	17.2	17.6	18.2
Professional Hygiene	22.0	28.8	28.7	28.9	21.4	24.6	28.0	22.7	18.6
Total	16.7	17.1	17.7	18.5	17.2	17.1	17.2	15.8	15.2

Operating cash flow

SEKm	2025:1	2024:4	2024:3	2024:2	2024:1	2023:4	2023:3	2023:2	2023:1
Health & Medical	1,232	976	1,674	879	1,330	1,411	1,676	323	270
Consumer Goods	1,657	1,114	2,793	1,442	2,331	2,506	2,235	1,732	1,760
Professional Hygiene	1,054	1,678	2,153	1,538	780	2,227	2,370	1,782	951
Other	-178	-471	-167	-620	-188	-230	-227	-990	-111
Total	3,765	3,297	6,453	3,239	4,253	5,914	6,054	2,847	2,870

[&]quot;) Of this amount, SEK 5,092m represents a liability relating to the dividend for Essity's shareholders paid on April 5, 2023 as decided at the Annual General Meeting on March 29, 2023.

Invitation to presentation

President and CEO Magnus Groth and Executive Vice President and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET on April 24, 2025.

Link to the live presentation, which can also be viewed afterwards: https://essitv.videosvnc.fi/2025-04-24-a1

Contact information for conference call with the possibility to ask questions:

UK: +44 (0) 33 0551 02 00 USA: +1 786 697 35 01 SWE: +46 (0) 8 505 204 24

Please call in well in advance of the start of the presentation. Indicate: "Essity".

For additional information, please contact:

Fredrik Rystedt, Executive Vice President and CFO, tel: +46 (0) 8 788 51 31 Sandra Åberg, Vice President Investor Relations, tel: +46 (0) 70 564 96 89 Per Lorentz, Vice President Corporate Communications, tel: +46 (0) 73 313 30 55

Calendar 2025-2026

Interim report, Quarter 2, 2025 Interim report, Quarter 3, 2025 Interim report, Quarter 4 and full-year, 2025 **Annual Report 2025**

July 17, 2025 October 23, 2025 January 22, 2026 March 2026

Essity is a global, leading hygiene and health company. Every day, our products, solutions and services are used by a billion people around the world. Our purpose is to break barriers to well-being for the benefit of consumers, patients, caregivers, customers and society. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands such as Actimove, Cutimed, JOBST, Knix, Leukoplast, Libero, Libresse, Lotus, Modibodi, Nosotras, Saba, Tempo, TOM Organic and Zewa. In 2024, Essity had net sales of approximately SEK 146bn (EUR 13bn) and employed 36,000 people. The company's headquarter is in Stockholm, Sweden and Essity is listed on Nasdag Stockholm.

More information at essity.com and follow Essity on social media.























